To increase clinical relevance we analyzed published results of clinical trials23,24,25 and reported blood tumor barrier (BTB) penetration26,27 of the WEE1 inhibitor adavosertib and the ATM/ATR inhibitor BAY-1895344. The gene discussed is WEE1; the disease is neoplasm.